A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
Part of paid clinical trials in Tempe, Arizona.
- Sponsor
- Keryx Biopharmaceuticals
- Study ID
- NCT01191255
- Phase
- PHASE3
- Status
- Completed
Conditions
- Hyperphosphatemia
- Kidney Failure
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ferric citrate, ca acetate, sevelamer carbonate, placebo — DRUGAll intervention doses will be based on serum phosphorus levels and/or drug label requirements
Study Details
This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.
Key Dates
- Start date
- Oct 31, 2010
- Status verified
- Dec 2014
- Primary completion
- Jan 31, 2013
- Completion
- Feb 28, 2013
Study Design
- Enrollment
- 441 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- FACTORIAL
- Primary purpose
- PREVENTION
Arms
- Active Comparator: Active ControlPhosLo (calcium acetate) Renvela (sevelamer carbonate)
- Placebo Comparator: PlaceboPlacebo
- Experimental: KRX-0502 (Ferric Citrate)ferric citrate
Primary Outcome Measure
Change in Mean Serum Phosphorus From Baseline (Week 52) to the End of the Efficacy Assessment Period (EAP; Week 56) [ Time Frame: 4 weeks ]
Locations (52)
Find similar trials in Tempe, AZ
By research site
Southwest Clinical Research Institute, LLC· Tempe, AZTower Nephrology Medical Group· Los Angeles, CAVeterans Administration Greater Los Angeles Healthcare System, West Los Angeles· Los Angeles, CAApex Research of Riverside· Riverside, CAAmerican Institute of Research· Whittier, CAUniversity of Colorado Denver· Aurora, CO
Related Studies
- Shingrix in Renal Transplant RecipientsPHASE3 · Recruiting · University of Colorado, Denver · Aurora, Colorado
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Phoenix, Arizona
- A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal DiseaseRecruiting · W.L.Gore & Associates · Phoenix, Arizona
- CAR-T Cell Therapy for Desensitization in Kidney TransplantationPHASE1 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Boston, Massachusetts